Based on this, it can be concluded that the peptide affects immune response, but also the body's regenerative processes at a cellular level
The tripeptide complex known as GHK-Cu (glycyl-L-histidyl-L-lysine complexed with copper(II)) has emerged as an intriguing molecule in modern biochemical and regenerative research
BGXs aggregate liability arising from an order will not exceed the amount paid for the product giving rise to the claim
The 2026 broader peptide-therapy reviews (PMID 41966639) place this compound class in the wider research-context of unapproved compounds under active investigation
Research peptides do not fall under the same drug approval framework as traditional pharmaceuticals, meaning GHK-Cu products cannot make therapeutic claims and are sold for research purposes only
however, differences in injection frequency, dose escalation, and device design meant that investigators were not blinded to which active treatment participants received [1]
